



PATENT  
675301-2017

C of C \$

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Gholam Peyman

Application No. : 10/631,143

Group Art Unit: 1615

Filing Date : July 31, 2003

Examiner: Humera N. Sheikh

For : Treatment Of Ocular Disease

Patent No. : 7,083,802

Issue Date : August 1, 2006

745 Fifth Avenue, New York, NY 10151

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Anne-Marie C. Yvon, Reg. No. 52,390

Name of Applicant, Assignee or Registered Representative

*Anne-Marie C. Yvon*

Signature

September 11, 2006

Date of Signature

**Certificate**  
**SEP 18 2006**  
**of Correction**

**REQUEST FOR CERTIFICATE OF CORRECTION**

Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

It is requested that a Certificate of Correction be issued in the above-entitled patent in accordance with the accompanying form PTO 1050. Please make the following changes:

09/15/2006 DEMMANU1 00000051 7083802

01 FC:1811

100.00 0P

SEP 19 2006

**IN THE CLAIMS:**

Column 10, claim 1 line 10 and  
line 20

A method to treat a posterior segment ocular condition selected from diabetic retinopathy, retinitis pigmentosa, "or" --and-- age related macular degeneration in a patient comprising intraocularly administering a composition comprising a drug selected from the group consisting of rapamycin, ascomycin, and combinations thereof, the drug at a concentration up to about 200  $\mu\text{g/ml}$  in a pharmaceutically acceptable formulation effective to treat the diabetic retinopathy, retinitis pigmentosa, or age related macular degeneration condition without substantial toxicity wherein the composition is administered by "at least one of" intraocular injection.

Column 10, Claim 3, line 25 and  
line 36

A method to treat a posterior segment ocular condition selected from diabetic retinopathy, retinitis pigmentosa "or" --and-- age related macular degeneration in a patient comprising intraocularly administering a composition consisting essentially of rapamycin in a pharmaceutically acceptable formulation effective to treat the diabetic retinopathy, retinitis pigmentosa, or age related macular degeneration condition by a method selected from the group consisting of topical administration at a concentration of about 50  $\text{pg/ml}$  to less than 1  $\mu\text{g/ml}$ , subconjunctival injection at a dose in the range of about 1  $\text{ng/ml}$  to about 200  $\mu\text{g/ml}$ , intravitreal injection at a dose in the range of about 1  $\text{ng}/0.1 \text{ ml}$  to about 20  $\mu\text{g/ml}$ , "or" --and-- retrobulbar injection at a dose in the range of about 20  $\mu\text{g/ml}$  to about 200  $\mu\text{g/ml}$ .

Column 10, Claim 5, line 46

An ocular treatment method comprising intraocularly administering to a patient after corneal surgery a composition consisting essentially of rapamycin in a pharmaceutically acceptable formulation and in an amount effective to enhance post-surgical ocular moisture in the patient wherein the composition is administered at a concentration up to about 200  $\mu\text{g/ml}$  by "at least one of" intraocular injection, or the composition is administered topically at a concentration in the range between about 50  $\text{pg/ml}$  to less than 1  $\mu\text{g/ml}$ .

Column 10, Claim 7, line 61

An ocular treatment method comprising intraocularly administering to a patient after corneal surgery a

composition consisting essentially of ascomycin in a pharmaceutically acceptable formulation and in an amount effective to enhance post-surgical ocular moisture in the patient wherein the composition is administered at a concentration up to about 200  $\mu\text{g/ml}$  by "at least one of" intraocular injection, or the composition is administered topically at a concentration in the range between about 50  $\text{pg/ml}$  to less than 1  $\mu\text{g/ml}$ .

Column 11, Claim 9, line 9

A method to treat an ocular condition in a patient comprising intraocularly administering to the patient a pharmaceutically acceptable formulation of a drug selected from the group consisting of rapamycin, ascomycin and combinations thereof, in an amount up to about 200  $\mu\text{g/ml}$  effective to treat an ocular condition selected from diabetic retinopathy, retinitis "pigmentosa, or " --pigmentosa, and-- age related macular degeneration without substantial toxicity and at least one antibiotic, wherein the composition is administered by "at least one of" intraocular injection at a concentration up to about 200  $\mu\text{g/ml}$ , or the composition is administered topically at a concentration in the range between about 50  $\text{pg/ml}$  to less than 1  $\mu\text{g/ml}$ .

Column 12, Claim 10, line 1  
and line 11

A method to treat an ocular posterior segment condition selected from diabetic retinopathy, retinitis pigmentosa, "or" --and-- age related macular degeneration in a patient comprising intraocularly administering a composition consisting essentially of ascomycin in a pharmaceutically acceptable formulation effective to treat the diabetic retinopathy, retinitis pigmentosa, or age related macular degeneration condition by a method selected from the group consisting of topical administration at a concentration between about 50  $\text{pg/ml}$  to less than 1  $\mu\text{g/ml}$ , subconjunctival injection at a dose in the range of about 1  $\text{ng/ml}$  to about 200  $\mu\text{g/ml}$ , intravitreal injection at a dose in the range of about 1  $\text{ng}/0.1 \text{ ml}$  to about 200  $\mu\text{g/ml}$ , "or" --and-- retrobulbar injection at a dose in the range of about 20  $\mu\text{g/ml}$  to about 200  $\mu\text{g/ml}$ .

**REMARKS**

Since the errors to be corrected are the Applicant's errors, check No. 41225 of \$100 is enclosed for payment of the fee. The requested changes do not constitute new matter and this application does not require re-examination. A completed Form PTO 1050 is enclosed. The Commissioner is authorized to charge any additional fees or credit any overpayments to Deposit Account No. 50-0320.

Respectfully submitted,  
FROMMER LAWRENCE & HAUG LLP  
Attorney for Applicant

By: Anne-Marie C. Yvon  
Thomas J. Kowalski  
Reg. No. 32,147  
Anne-Marie C. Yvon  
Reg. No. 52,390  
Tel.: (212) 588-0800

SEP 19 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.  
(Also Form PTO-1050)

## UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,083,802  
DATED : August 1, 2006  
INVENTOR(S) : Gholam Peyman

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

**In The Claims:**

Column 10, Claim 1, line 11	"or" should be --and--
Column 10, Claim 1, line 20	delete "at least one of"
Column 10, Claim 3, line 25	"or" should be --and--
Column 10, Claim 3, line 36	"or" should be --and--
Column 10, Claim 5, line 46	delete "at least one of"
Column 10, Claim 7, line 61	delete "at least one of"
Column 11, Claim 9, line 9	"pigmentosa, or" should b --pigmentosa, and--
Column 11, Claim 9, line 11	delete "at least one of"
Column 12, Claim 10, line 1	"or" should be --and--
Column 12, Claim 10, line 11	"or" should be --and--

**MAILING ADDRESS OF SENDER:**

Thomas J. Kowalski, Esq.  
Frommer Lawrence & Haug LLP  
745 Fifth Avenue  
New York, New York 10151

PATENT NO. 7,083,802  
No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.1 and 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing, and submitting the complete provisional application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

00396329

SEP 19 2006